| Literature DB >> 35936336 |
Marcello Passarelli1, Laura Casetta2, Luca Rizzi2, Raffaella Perrella3, Giuseppe Maniaci4, Daniele La Barbera4.
Abstract
In the present study we analyzed how attitudes toward touch have changed during the COVID-19 pandemic in an Italian sample, through two different studies: in the first we contacted participants of the Italian validation study of the Touch Avoidance Questionnaire, asking them to take part in a follow-up study (N = 31, 64.5% women, age 42.58 ± 15.15); in the second we recruited a new sample of 717 people (73.92% women, age 34.25 ± 13.11), comparing it to the full validation sample of the Touch Avoidance Questionnaire (N = 335, 64.48% women, age = 35.82 ± 14.32) to further investigate the relationship between the pandemic, stress responses, fear of contagion, anxiety, and attitudes toward touch. Overall, we found higher post-pandemic scores for touch avoidance toward strangers and family members and lower scores in touch avoidance toward friends of either gender, along with a slight increase in anxiety and stress. Touch avoidance was also positively related to anxiety and/or stress levels except for touch avoidance toward same-sex friends, for which the relationship with anxiety was negative. Surprisingly, we found that young people were the most anxious, despite older people being more at-risk of dying from COVID-19. Women were slightly more stressed out. COVID-19-related fears were significant predictors of touch avoidance toward partners, friends and strangers, but not of touch avoidance toward family. The results suggest that touch avoidance increased during the pandemic (except toward same-sex friends), together with anxiety and stress levels, but the change was relatively small.Entities:
Keywords: COVID-19; attitudes toward touch; fear of contagion; pandemic effects; touch avoidance
Year: 2022 PMID: 35936336 PMCID: PMC9354952 DOI: 10.3389/fpsyg.2022.854110
Source DB: PubMed Journal: Front Psychol ISSN: 1664-1078
Pre-post comparisons for the scores on each subscale.
| (Sub)scale | Difference (post—pre) |
|
|
|
| TAQ partner | 0.01 | 195 | 0.542 | 0.01 (negligible) |
| TAQ family | −0.07 | 138 | 0.392 | 0.07 (negligible) |
| TAQ same sex | 0.23 | 185 | 0.392 | 0.34 (small) |
| TAQ opposite sex | 0.05 | 209 | 0.900 | 0.07 (negligible) |
| TAQ stranger | 0.78 | 315 | <0.001 | 1.02 (large) |
| MSP | −0.12 | 178 | 0.392 | 0.27 (negligible) |
| STAI-Y1 | −0.02 | 192 | 0.900 | 0.05 (negligible) |
***significant for p < 0.001. All p-values are adjusted for multiple comparisons using Benjamini-Hochberg’s correction.
Path analysis predicting MSP and STAI-Y1 scores.
| Scale | Predictor | β |
|
|
| MSP (Post) | Age | −0.49 | −2.78 | 0.005 |
| Gender (male) | 0.00 | 0.01 | 0.995 | |
| TAQ partner | −0.08 | −0.33 | 0.741 | |
| TAQ family | −0.03 | −0.11 | 0.911 | |
| TAQ same sex | −0.35 | −1.72 | 0.086 | |
| TAQ opposite sex | 0.26 | 1.21 | 0.228 | |
| TAQ stranger | −0.33 | −1.90 | 0.057 | |
| STAI-Y1 (Post) | Age | −0.47 | −2.56 | 0.010 |
| Gender (male) | −0.08 | −0.45 | 0.656 | |
| TAQ partner | 0.08 | 0.31 | 0.758 | |
| TAQ family | 0.02 | 0.07 | 0.947 | |
| TAQ same sex | −0.01 | −0.03 | 0.973 | |
| TAQ opposite sex | −0.15 | −0.66 | 0.512 | |
| TAQ stranger | −0.26 | −1.46 | 0.144 |
*Significant for p < 0.05, **significant for p < 0.01.
Pre-post comparisons for the scores on each subscale.
| (Sub)scale | Pre-COVID score | Post-COVID score |
|
|
|
|
| TAQ partner | 1.94 | 1.94 | 0.05 | 747.45 | 0.959 | 0.00 (negligible) |
| TAQ family | 2.65 | 2.86 | −3.24 | 679.52 | <0.001 | 0.21 (small) |
| TAQ same sex | 2.07 | 1.92 | 2.96 | 725.95 | <0.003 | 0.19 (negligible) |
| TAQ opposite sex | 2.16 | 2.02 | 2.63 | 744.98 | 0.008 | 0.17 (negligible) |
| TAQ stranger | 2.62 | 2.83 | −3.66 | 715.88 | <0.001 | 0.23 (small) |
| MSP | 1.89 | 2.13 | −7.04 | 767.82 | <0.001 | 0.44 (small) |
| STAI-Y1 | 2.60 | 2.77 | −4.67 | 765.46 | <0.001 | 0.29 (small) |
**significant for p < 0.01, ***significant for p < 0.001.
Path analysis predicting MSP and STAI-Y1 scores.
| Scale | Predictor | β |
|
|
| MSP | Age (Over 60) | −0.10 | −2.95 | 0.003 |
| Gender (Male) | −0.08 | −2.16 | 0.031 | |
| Vaccinated (Yes) | −0.01 | −0.43 | 0.667 | |
| Knows people who died from COVID-19 (Yes) | 0.05 | 1.40 | 0.162 | |
| TAQ partner | 0.09 | 2.62 | 0.009 | |
| TAQ family | 0.16 | 4.57 | <0.001 | |
| TAQ same sex | −0.08 | −1.77 | 0.077 | |
| TAQ opposite sex | 0.03 | 0.64 | 0.522 | |
| TAQ stranger | 0.11 | 2.86 | 0.004 | |
| MAC-RF1 (Fears related to the body) | 0.08 | 1.76 | 0.079 | |
| MAC-RF2 (Fears related to meaningful relationships) | 0.00 | 0.13 | 0.897 | |
| MAC-RF3 (Difficulties in cognitive monitoring of concerns) | 0.12 | 2.96 | 0.003 | |
| MAC-RF4 (Behavioral difficulties related to fear) | 0.37 | 8.39 | <0.001 | |
| STAI-Y1 | Age (Over 60) | −0.09 | −2.74 | 0.006 |
| Gender (Male) | 0.03 | 0.91 | 0.365 | |
| Vaccinated (Yes) | −0.03 | −0.80 | 0.426 | |
| Knows people who died from COVID-19 (Yes) | −0.04 | −1.30 | 0.194 | |
| TAQ partner | 0.13 | 3.61 | <0.001 | |
| TAQ family | 0.15 | 4.31 | <0.001 | |
| TAQ same sex | −0.15 | −3.40 | 0.001 | |
| TAQ opposite sex | 0.11 | 2.50 | 0.012 | |
| TAQ stranger | 0.10 | 2.65 | 0.008 | |
| MAC-RF1 (Fears related to the body) | 0.00 | −0.05 | 0.957 | |
| MAC-RF2 (Fears related to meaningful relationships) | 0.13 | 2.72 | 0.007 | |
| MAC-RF3 (Difficulties in cognitive monitoring of concerns) | 0.07 | 1.69 | 0.091 | |
| MAC-RF4 (Behavioral difficulties related to fear) | 0.36 | 8.25 | <0.001 | |
| TAQ partner | Gender (Male) | −0.00 | −0.09 | 0.928 |
| Age (Over 60) | 0.08 | 1.94 | 0.052 | |
| Vaccinated (Yes) | −0.08 | −1.97 | 0.049 | |
| Knows people who died from COVID-19 (Yes) | 0.01 | 1.16 | 0.871 | |
| MAC-RF1 (Fears related to the body) | 0.01 | 0.22 | 0.829 | |
| MAC-RF2 (Fears related to meaningful relationships) | −0.12 | −2.17 | 0.030 | |
| MAC-RF3 (Difficulties in cognitive monitoring of concerns) | 0.05 | 0.94 | 0.348 | |
| MAC-RF4 (Behavioral difficulties related to fear) | 0.09 | 1.76 | 0.078 | |
| TAQ family | Gender (Male) | 0.09 | 2.29 | 0.022 |
| Age (Over 60) | 0.04 | 0.97 | 0.334 | |
| Vaccinated (Yes) | −0.10 | −2.35 | 0.019 | |
| Knows people who died from COVID-19 (Yes) | 0.04 | 1.03 | 0.302 | |
| MAC-RF1 (Fears related to the body) | −0.01 | −0.22 | 0.824 | |
| MAC-RF2 (Fears related to meaningful relationships) | −0.06 | −1.10 | 0.272 | |
| MAC-RF3 (Difficulties in cognitive monitoring of concerns) | 0.02 | 0.33 | 0.740 | |
| MAC-RF4 (Behavioral difficulties related to fear) | 0.05 | 0.99 | 0.320 | |
| TAQ same Sex | Gender (Male) | 0.25 | 6.36 | <0.001 |
| Age (Over 60) | 0.13 | 3.27 | 0.001 | |
| Vaccinated (Yes) | 0.00 | 0.01 | 0.992 | |
| Knows people who died from COVID-19 (Yes) | 0.00 | 0.06 | 0.952 | |
| MAC-RF1 (Fears related to the body) | 0.07 | 1.25 | 0.213 | |
| MAC-RF2 (Fears related to meaningful relationships) | −0.05 | −0.94 | 0.347 | |
| MAC-RF3 (Difficulties in cognitive monitoring of concerns) | 0.09 | 1.87 | 0.062 | |
| MAC-RF4 (Behavioral difficulties related to fear) | 0.11 | 2.22 | 0.026 | |
| TAQ opposite sex | Gender (Male) | −0.06 | −1.53 | 0.127 |
| Age (Over 60) | 0.12 | 2.97 | 0.003 | |
| Vaccinated (Yes) | −0.04 | −0.90 | 0.371 | |
| Knows people who died from COVID-19 (Yes) | 0.04 | 1.14 | 0.253 | |
| MAC-RF1 (Fears related to the body) | 0.07 | 1.27 | 0.205 | |
| MAC-RF2 (Fears related to meaningful relationships) | −0.09 | −1.65 | 0.099 | |
| MAC-RF3 (Difficulties in cognitive monitoring of concerns) | 0.14 | 2.88 | 0.004 | |
| MAC-RF4 (Behavioral difficulties related to fear) | 0.12 | 2.24 | 0.025 | |
| TAQ stranger | Gender (Male) | 0.03 | 0.69 | 0.493 |
| Age (Over 60) | 0.02 | 0.39 | 0.697 | |
| Vaccinated (Yes) | 0.01 | 0.26 | 0.794 | |
| Knows people who died from COVID-19 (Yes) | 0.01 | 0.23 | 0.821 | |
| MAC-RF1 (Fears related to the body) | 0.13 | 2.31 | 0.021 | |
| MAC-RF2 (Fears related to meaningful relationships) | 0.12 | 2.09 | 0.037 | |
| MAC-RF3 (Difficulties in cognitive monitoring of concerns) | 0.08 | 1.57 | 0.116 | |
| MAC-RF4 (Behavioral difficulties related to fear) | 0.03 | 0.57 | 0.572 |
*Significant for p < 0.05, **significant for p < 0.01, ***significant for p < 0.001.